Coronado Biosciences (NASDAQ: CNDO) Stocks Are Correcting Today
Coronado Biosciences (NASDAQ: CNDO) announced yesterday that it has formed a company called Mustang Therpeutics that will develop and commercialize a portfolio of CAR-T cells. As a result, the stock jumped by more than 60% in mid-day trading. However, the stock seems to be down today and in a big way. Coronado Biosciences is down 7.55% so far today (10:55); trading at $3.89 per share.
Outlook – When we see massive gains, we usually see drops following as investors level out the market. I believe that what we’re seeing today is a mini-market correction. While the stock may end in the red today, I’m expecting to see more upward movement next week.
Inovio Pharmaceuticals (NASDAQ: INO) Stocks Are Climbing Again Today
Inovio Pharmaceuticals (NASDAQ: INO) stocks have been all over the place lately. Following their earnings report, which in my opinion was very poor, the company’s stock skyrocketed. Since then, we’ve seen corrections and more uptrends. Well, today the stock is headed up. Currently (11:00), Inovio Pharmaceuticals is trading for $9.7 per share after a gain of 2.75% so far today.
Outlook – When it comes to Inovio Pharmaceuticals, I was very put off by their earnings report. While the stock does seem to be on the uptrend overall, I’m not so sure that I’d be willing to bet my green backs that it will stay on that trend.
Amarin (NASDAQ: AMRN) Stocks Seem Confused Today
We’ve seen quite the roller coaster in Amarin (NASDAQ: AMRN) stocks recently. Following a major analyst upgrade last week, the stock climbed by more than 40% between Thursday morning and the closing bell on Friday. However, this week has been a bit choppy. We saw a correction Monday and Tuesday, great growth on Wednesday, another correction yesterday, and for the time being, a relatively flat chart today. Currently (11:04), Amarin is down 0.20%, trading at $2.55 per share.
Outlook – When it comes to Amarin, I’m willing to break my golden “Don’t invest in losing companies” rule. While the company is operating at a loss, it has been able to shrink that loss dramatically through Q4. With analyst upgrades keeping investors excited, and the company’s dominance in the fields it touches, I think this one will get to profits in the long term.
Biogen Idec (NASDAQ: BIIB) Stocks Are Climbing On Great News
Biogen Idec (NASDAQ: BIIB) recently announced that data from an interim analysis of a phase 1b study of aducanumab showed that the new drug demonstrates an acceptable safety profile. Other positive news became available as well. As a result, we’ve seen a decent climb in Biogen Idec stocks today. Currently (10:10), the stock is trading at $462.67 per share after a gain of 6.69% so far today.
Outlook – In my humble opinion, Biogen Idec stocks will continue to grow. The company has proven time and time again that it is capable of innovating new solutions to some of the most pressing medical issues. Overall, I’d be surprised to see this stock fall for anything more than a short period of time.
Amicus Therapeutics (NASDAQ: FOLD) Stocks Are Correcting Today
Yesterday Amicus Therapeutics (NASDAQ: FOLD) stocks soared; climbing by nearly 30% throughout the day. The climb happened after the company announced that it will seek an accelerated approval rating for one of its new medications. Today however, the stock is down a bit as the growth we saw yesterday proved to be too much too fast. Currently (11:16), Amicus Therapeutics is trading for $11.73 per share after a loss of 5.86% so far today.
Outlook – Amicus Therapeutics is another stock that I think will show great growth over the long run. The company has a proven ability to solve problems and focus on growth; that’s always a good note in my book!
What Are Your Thoughts
Do you have an opinion on any of the stocks mentioned here? We’d love to see it in the comments below!